WO2009079587A3 - Biomarkers for sensitivity to anti-igf1r therapy - Google Patents

Biomarkers for sensitivity to anti-igf1r therapy Download PDF

Info

Publication number
WO2009079587A3
WO2009079587A3 PCT/US2008/087240 US2008087240W WO2009079587A3 WO 2009079587 A3 WO2009079587 A3 WO 2009079587A3 US 2008087240 W US2008087240 W US 2008087240W WO 2009079587 A3 WO2009079587 A3 WO 2009079587A3
Authority
WO
WIPO (PCT)
Prior art keywords
biomarkers
sensitivity
methods
igf1r
therapy
Prior art date
Application number
PCT/US2008/087240
Other languages
French (fr)
Other versions
WO2009079587A2 (en
Inventor
Yan Wang
Yaolin Wang
Diane Levitan
Cynthia Seidel-Dugan
Ming Liu
Wei Ding
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to US12/808,270 priority Critical patent/US20110091524A1/en
Priority to EP08861138A priority patent/EP2247757A2/en
Priority to CA2709827A priority patent/CA2709827A1/en
Priority to MX2010006854A priority patent/MX2010006854A/en
Priority to JP2010539750A priority patent/JP2011505873A/en
Publication of WO2009079587A2 publication Critical patent/WO2009079587A2/en
Publication of WO2009079587A3 publication Critical patent/WO2009079587A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Business, Economics & Management (AREA)
  • Business, Economics & Management (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides, for example, methods for conveniently determining if a cancerous condition in a subject will be responsive to an IGF1R inhibitor. The invention includes patient selection methods and methods of treatment.
PCT/US2008/087240 2007-12-18 2008-12-17 Biomarkers for sensitivity to anti-igf1r therapy WO2009079587A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/808,270 US20110091524A1 (en) 2007-12-18 2008-12-17 Biomarkers for sensitivity to anti-igf1r therapy
EP08861138A EP2247757A2 (en) 2007-12-18 2008-12-17 Biomarkers for sensitivity to anti-igf1r therapy
CA2709827A CA2709827A1 (en) 2007-12-18 2008-12-17 Biomarkers for sensitivity to anti-igf1r therapy
MX2010006854A MX2010006854A (en) 2007-12-18 2008-12-17 Biomarkers for sensitivity to anti-igf1r therapy.
JP2010539750A JP2011505873A (en) 2007-12-18 2008-12-17 Biomarkers of sensitivity to anti-IGF1R therapy

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US1455607P 2007-12-18 2007-12-18
US61/014,556 2007-12-18
US1593807P 2007-12-21 2007-12-21
US61/015,938 2007-12-21
US2290908P 2008-01-23 2008-01-23
US61/022,909 2008-01-23

Publications (2)

Publication Number Publication Date
WO2009079587A2 WO2009079587A2 (en) 2009-06-25
WO2009079587A3 true WO2009079587A3 (en) 2009-11-12

Family

ID=40796133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/087240 WO2009079587A2 (en) 2007-12-18 2008-12-17 Biomarkers for sensitivity to anti-igf1r therapy

Country Status (6)

Country Link
US (1) US20110091524A1 (en)
EP (1) EP2247757A2 (en)
JP (2) JP2011505873A (en)
CA (1) CA2709827A1 (en)
MX (1) MX2010006854A (en)
WO (1) WO2009079587A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102886045A (en) 2005-02-03 2013-01-23 综合医院公司 Method for treating gefitinib resistant cancer
EP1942937A1 (en) 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
PE20090368A1 (en) 2007-06-19 2009-04-28 Boehringer Ingelheim Int ANTI-IGF ANTIBODIES
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
PL2310011T3 (en) 2008-06-17 2013-12-31 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
SG10202102855RA (en) 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
BRPI0923359B8 (en) 2008-12-12 2021-05-25 Boehringer Ingelheim Int anti-igf antibody molecule, method for producing the same, DNA molecule, expression vector, and pharmaceutical composition and in vitro method for inhibiting the binding of igf-1 and igf-2 to the igf-1 receptor and to the insulin receptor go-to
MX356593B (en) 2009-04-06 2018-06-05 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer.
CN102655864A (en) * 2009-11-18 2012-09-05 赫尔辛医疗股份公司 Compositions and methods for treating centrally mediated nausea and vomiting
US9110082B2 (en) 2009-11-30 2015-08-18 Merck Sharp & Dohme Corp. Methods for the identification and treatment of patients sensitive to anti IGF-1R inhibition therapy
JP2014510265A (en) 2011-02-02 2014-04-24 アムジェン インコーポレイテッド Methods and compositions for inhibition of IGF-IR
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012175481A1 (en) * 2011-06-20 2012-12-27 Institut Curie Compositions and methods for treating leukemia
US20150258170A1 (en) * 2012-10-10 2015-09-17 The Trustees Of Columbia University In The City Of New York Diagnosis and Treatment of SMA and SMN Deficiency
US10106855B2 (en) 2012-11-09 2018-10-23 The Johns Hopkins University Genetic assay to determine prognosis in Polycythemia Vera patients
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
SG11201601424PA (en) 2013-08-28 2016-03-30 Stemcentrx Inc Site-specific antibody conjugation methods and compositions
JP2017514143A (en) 2014-02-21 2017-06-01 アッヴィ・ステムセントルクス・エル・エル・シー Anti-DLL3 antibodies and drug conjugates for use in melanoma
EP3550306B1 (en) * 2014-08-26 2021-03-03 Keio University Anti-cancer agent sensitivity-determining marker
US20170372347A1 (en) * 2016-06-22 2017-12-28 International Business Machines Corporation Sequence-based marketing attribution model for customer journeys
EP3665307B1 (en) * 2017-08-10 2022-09-28 The Institute of Cancer Research: Royal Cancer Hospital Materials and methods for stratifying and treating cancers
CN107714719A (en) * 2017-11-08 2018-02-23 上海市第妇婴保健院 Application of the rapamycin in the medicine for preparing treatment IL-27 low expression carcinoma of endometrium
CN111394462A (en) * 2020-04-13 2020-07-10 浙江大学 Liver cancer sorafenib drug-resistant circRNA marker and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087756A2 (en) * 2003-04-02 2004-10-14 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2006060419A2 (en) * 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
US20070065858A1 (en) * 2005-09-20 2007-03-22 Haley John D Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20070148145A1 (en) * 2005-12-16 2007-06-28 The Board Of Trustees Of The Leland Stanford Junior University Protein modulators of resistance to alkylating agents
WO2008076278A2 (en) * 2006-12-13 2008-06-26 Schering Corporation Methods of cancer treatment with igf1r inhibitors
WO2008144345A2 (en) * 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856094A (en) * 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US5989885A (en) * 1997-01-10 1999-11-23 Myriad Genetics, Inc. Specific mutations of map kinase 4 (MKK4) in human tumor cell lines identify it as a tumor suppressor in various types of cancer
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
US20080193445A1 (en) * 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
KR101086533B1 (en) * 2002-05-24 2011-11-23 쉐링 코포레이션 Neutralizing human anti-IGFR antibody, a method for producing it and a composition comprising it
WO2005056764A2 (en) * 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
AU2006236637B2 (en) * 2005-04-15 2012-09-06 Merck Sharp & Dohme Corp. Methods and compositions for treating or preventing cancer
WO2008005469A2 (en) * 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087756A2 (en) * 2003-04-02 2004-10-14 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2006060419A2 (en) * 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
US20060140960A1 (en) * 2004-12-03 2006-06-29 Schering Corporation Biomarkers for pre-selection of patients for anti-IGF1R therapy
US20070065858A1 (en) * 2005-09-20 2007-03-22 Haley John D Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20070148145A1 (en) * 2005-12-16 2007-06-28 The Board Of Trustees Of The Leland Stanford Junior University Protein modulators of resistance to alkylating agents
WO2008076278A2 (en) * 2006-12-13 2008-06-26 Schering Corporation Methods of cancer treatment with igf1r inhibitors
WO2008144345A2 (en) * 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHE DECHAMPS ET AL: "The Tre2 Oncoprotein, Implicated in Ewing's Sarcoma, Interacts with Two Components of the Cytoskeleton", BIOTECHNOLOGY LETTERS, KLUWER ACADEMIC PUBLISHERS, DO, vol. 28, no. 4, 1 February 2006 (2006-02-01), pages 223 - 231, XP019231204, ISSN: 1573-6776 *
LI S-L ET AL: "Single-chain Antibodies Against Human Insulin-like Growth Factor I Receptor: Expression, Purification and Effect on Tumor Growth", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, SPRINGER-VERLAG, BERLIN, DE, vol. 49, no. 4/05, 1 July 2000 (2000-07-01), pages 243 - 252, XP001113064, ISSN: 0340-7004 *
MITSIADES CONSTANTINE S ET AL: "Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors", CANCER CELL, CELL PRESS, US, vol. 5, no. 3, 1 March 2004 (2004-03-01), pages 221 - 230, XP009100737, ISSN: 1535-6108 *
OZBAS-GERCEKER F ET AL: "Serial analysis of gene expression in the hippocampus of patients with mesial temporal lobe epilepsy", NEUROSCIENCE, NEW YORK, NY, US, vol. 138, no. 2, 1 January 2006 (2006-01-01), pages 457 - 474, XP024986562, ISSN: 0306-4522, [retrieved on 20060101] *
RIEDEMANN J ET AL: "IGF1R signalling and its inhibition", ENDOCRINE-RELATED CANCER, JOURNAL OF ENDOCRINOLOGY LTD., BRISTOL, GB, vol. 13, no. SUPPL. 1, 1 December 2006 (2006-12-01), pages S33 - S43, XP002481460, ISSN: 1351-0088 *

Also Published As

Publication number Publication date
WO2009079587A2 (en) 2009-06-25
CA2709827A1 (en) 2009-06-25
US20110091524A1 (en) 2011-04-21
JP2013078341A (en) 2013-05-02
MX2010006854A (en) 2010-09-09
JP2011505873A (en) 2011-03-03
EP2247757A2 (en) 2010-11-10

Similar Documents

Publication Publication Date Title
WO2009079587A3 (en) Biomarkers for sensitivity to anti-igf1r therapy
PH12017500930A1 (en) Hsp90 inhibitor combinations
WO2010056337A3 (en) Methods and systems of using exosomes for determining phenotypes
TW200742570A (en) Physiological function monitoring system
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
WO2011046964A3 (en) Inhibitors of bruton's tyrosine kinase
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
WO2007047955A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2011151252A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
WO2009126934A3 (en) Detection and tratment of pancreatic, ovarian and other cancers
WO2007067968A3 (en) Effects of inhibitors of fgfr3 on gene transcription
MX2010003424A (en) Measuring mechanical properties.
WO2012149493A3 (en) Hsp90 combination therapy
WO2009012140A3 (en) Drug selection for lung cancer therapy using antibody-based arrays
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
WO2007123722A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2008131361A3 (en) Biosensors for measuring analytes in the interstitial fluid
WO2012082494A3 (en) The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer
WO2006057997A3 (en) Plasmin-inhibitory therapies
WO2008070472A3 (en) Use of plasma hsp90 related to malignancy
WO2010009171A3 (en) Src activation for determining cancer prognosis and as a target for cancer therapy
WO2005080593A3 (en) P53 wild-type as biomarker for the treatment with mtor inhibitors in combination with a cytotoxic agent
WO2011074802A3 (en) Kit for diagnosing prostate cancer and diagnosis method
WO2009140505A3 (en) Methods and systems for detecting concealed objects
WO2010053816A3 (en) Biomarkers for diagnosis of breast cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08861138

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010539750

Country of ref document: JP

Ref document number: 2709827

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/006854

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008861138

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12808270

Country of ref document: US